https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct03174197-2026-09-23 Hipa.ai en 2026-09-23T00:00:00.000Z Atezolizumab results posted for newly diagnosed glioblastoma trial https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03425565-2026-09-22 Hipa.ai en 2026-09-22T00:00:00.000Z Pembrolizumab results posted for advanced gynecologic clear cell cancer https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct04810078-2026-09-22 Hipa.ai en 2026-09-22T00:00:00.000Z Nivolumab SC results show higher response rate in kidney cancer https://hipa.ai/drug/empagliflozin/updates/trial-results-posted-nct06435858-2026-09-22 Hipa.ai en 2026-09-22T00:00:00.000Z Empagliflozin posts electrolyte results in kidney disease trial https://hipa.ai/drug/empagliflozin/updates/trial-results-posted-nct06149793-2026-09-21 Hipa.ai en 2026-09-21T00:00:00.000Z Empagliflozin shows higher time in range in cystic fibrosis diabetes trial https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04032418-2026-09-21 Hipa.ai en 2026-09-21T00:00:00.000Z Pembrolizumab NSCLC trial posts results for 12-week dosing